Welcome to LookChem.com Sign In|Join Free

CAS

  • or
C28H47N3O6S is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

865460-03-3

Post Buying Request

865460-03-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

865460-03-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 865460-03-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,5,4,6 and 0 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 865460-03:
(8*8)+(7*6)+(6*5)+(5*4)+(4*6)+(3*0)+(2*0)+(1*3)=183
183 % 10 = 3
So 865460-03-3 is a valid CAS Registry Number.

865460-03-3Upstream product

865460-03-3Downstream Products

865460-03-3Relevant articles and documents

Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups

Venkatraman, Srikanth,Velazquez, Francisco,Wu, Wanli,Blackman, Melissa,Madison, Vincent,Njoroge, F. George

, p. 2151 - 2155 (2010)

Blood borne hepatitis C infections are the primary cause for liver cirrhosis and hepatocellular carcinoma. HCV NS3 protease, a pivotal enzyme in the replication cycle of HCV virus has been the primary target for development of new drug candidates. Boceprevir and telaprevir are two novel ketoamide derived inhibitors that are currently undergoing phase-III clinical trials. These inhibitors include ketoamide functionality as serine trap and have an acidic alpha-ketoamide center that undergoes epimerization under physiological conditions. Our initial attempts to arrest this epimerization by introducing quaternary amino acids at P1 had resulted in significantly diminished activity. In this manuscript we describe alpha quaternized P1 group that result in potent inhibitors in the enzyme assay and demonstrate cellular activity comparable to boceprevir.

SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE

-

Page/Page column 140, (2010/02/14)

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 865460-03-3